BioPharmaceutical Business Intelligence

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Queensland Health
Colorcon
QuintilesIMS
Harvard Business School
Express Scripts
Citi
Merck
Johnson and Johnson
US Army
Chubb

Generated: January 22, 2018

DrugPatentWatch Database Preview

PFIZER Company Profile

« Back to Dashboard

What is the competitive landscape for PFIZER, and what generic alternatives to PFIZER drugs are available?

PFIZER has one hundred and fifty-four approved drugs.

There are sixty-two US patents protecting PFIZER drugs and there have been two Paragraph IV challenges on PFIZER drugs in the past three years. There is one tentative approval on PFIZER drugs.

There are one thousand eight hundred and seventy patent family members on PFIZER drugs in seventy-nine countries and one hundred and fifty-eight supplementary protection certificates in fourteen countries.

Summary for PFIZER
International Patents:1870
US Patents:62
Tradenames:121
Ingredients:107
NDAs:154
Drug Master File Entries: 3

Drugs and US Patents for PFIZER

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Pfizer ATARAX hydroxyzine hydrochloride TABLET;ORAL 010392-005 Approved Prior to Jan 1, 1982 DISCN No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Pfizer CADUET amlodipine besylate; atorvastatin calcium TABLET;ORAL 021540-008 Jan 30, 2004 AB RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Pfizer Inc QUILLICHEW ER methylphenidate hydrochloride TABLET, EXTENDED RELEASE, CHEWABLE;ORAL 207960-003 Dec 4, 2015 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Pfizer Pharms NEURONTIN gabapentin CAPSULE;ORAL 020235-001 Dec 30, 1993 AB RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Pfizer Inc FRAGMIN dalteparin sodium INJECTABLE;SUBCUTANEOUS 020287-002 May 1, 2007 DISCN No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Pfizer LITHIUM CARBONATE lithium carbonate TABLET;ORAL 016834-001 Approved Prior to Jan 1, 1982 DISCN No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Pfizer TETRACYN tetracycline hydrochloride INJECTABLE;INJECTION 060096-002 Approved Prior to Jan 1, 1982 DISCN No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Pfizer VISTARIL hydroxyzine hydrochloride INJECTABLE;INJECTION 011111-002 Approved Prior to Jan 1, 1982 DISCN Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Pfizer GLUCOTROL glipizide TABLET;ORAL 017783-003 May 11, 1993 DISCN No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Pfizer PFIZERPEN G penicillin g potassium FOR SOLUTION;ORAL 060587-001 Approved Prior to Jan 1, 1982 DISCN No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for PFIZER

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Pfizer MINIPRESS prazosin hydrochloride CAPSULE;ORAL 017442-003 Approved Prior to Jan 1, 1982 ➤ Subscribe ➤ Subscribe
Pfizer CADUET amlodipine besylate; atorvastatin calcium TABLET;ORAL 021540-007 Jan 30, 2004 ➤ Subscribe ➤ Subscribe
Pfizer ZOLOFT sertraline hydrochloride TABLET;ORAL 019839-005 Mar 6, 1996 ➤ Subscribe ➤ Subscribe
Pfizer LIPITOR atorvastatin calcium TABLET;ORAL 020702-004 Apr 7, 2000 ➤ Subscribe ➤ Subscribe
Pfizer MINIPRESS XL prazosin hydrochloride TABLET, EXTENDED RELEASE;ORAL 019775-001 Jan 29, 1992 ➤ Subscribe ➤ Subscribe
Pfizer CARDURA doxazosin mesylate TABLET;ORAL 019668-004 Nov 2, 1990 ➤ Subscribe ➤ Subscribe
Pfizer Pharms REZULIN troglitazone TABLET;ORAL 020720-002 Jan 29, 1997 ➤ Subscribe ➤ Subscribe
Pfizer CADUET amlodipine besylate; atorvastatin calcium TABLET;ORAL 021540-003 Jan 30, 2004 ➤ Subscribe ➤ Subscribe
Pfizer ZOLOFT sertraline hydrochloride TABLET;ORAL 019839-005 Mar 6, 1996 ➤ Subscribe ➤ Subscribe
Pfizer CADUET amlodipine besylate; atorvastatin calcium TABLET;ORAL 021540-008 Jan 30, 2004 ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for PFIZER drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Extended-release Tablets 11 mg ➤ Subscribe 11/7/2016
➤ Subscribe Capsules 200 mg/38 mg ➤ Subscribe 2/16/2016
➤ Subscribe Capsules 0.125 mg, 0.25 mg, and 0.5 mg ➤ Subscribe 5/1/2014
➤ Subscribe Extended-release Tablets 4 mg and 8 mg ➤ Subscribe 10/31/2012
➤ Subscribe Sublingual Tablets 0.6 mg ➤ Subscribe 12/29/2011
➤ Subscribe For Injection 500 mg/vial ➤ Subscribe 6/17/2011
➤ Subscribe Tablets 0.5 mg and 1 mg ➤ Subscribe 5/10/2010
➤ Subscribe Tablets 20 mg and 40 mg ➤ Subscribe 3/29/2010
➤ Subscribe Tablets 2.5 mg/40 mg ➤ Subscribe 9/17/2009
➤ Subscribe Tablets 5 mg/80 mg ➤ Subscribe 4/7/2009
➤ Subscribe Tablets 5 mg/10 mg, 5 mg/20 mg, 5 mg/40 mg, 10 mg/10 mg, 10 mg/20 mg and 10 mg/80 mg ➤ Subscribe 12/29/2006
➤ Subscribe Tablets 150 mg and 200 mg ➤ Subscribe 11/9/2005
➤ Subscribe Sublingual Tablets 0.3 mg, 0.4 mg and 0.6 mg ➤ Subscribe 10/19/2005
➤ Subscribe Capsules 5 mg and 10 mg ➤ Subscribe 6/21/2005
➤ Subscribe Capsules 20 mg, 40 mg, 60 mg and 80 mg ➤ Subscribe 2/7/2005
➤ Subscribe Capsules 200 mg/30 mg ➤ Subscribe 12/27/2004
➤ Subscribe Tablets 25 mg and 50 mg ➤ Subscribe 11/19/2004
➤ Subscribe Tablets 100 mg ➤ Subscribe 10/25/2004
➤ Subscribe Injection 20 mg/mL, 2 mL and 5 mL vials ➤ Subscribe 7/26/2004
Premature patent expirations for PFIZER

Expiration due to failure to pay maintenance fee

Patent Number Expiration Date
➤ Subscribe ➤ Subscribe

Non-Orange Book US Patents for PFIZER

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,361,795 Method for lowering blood glucose ➤ Subscribe
7,205,300 Aryl fused azapolycyclic compounds ➤ Subscribe
6,407,236 Adenosine A3 receptor modulators ➤ Subscribe
7,521,069 Methods and compositions for pulmonary delivery of insulin ➤ Subscribe
6,028,214 GABA and L-glutamic acid analogs for antiseizure treatment ➤ Subscribe
6,262,120 GABA and L-glutamic acid analogs for antiseizure treatment ➤ Subscribe
6,165,463 Dispersible antibody compositions and methods for their preparation and use ➤ Subscribe
8,062,667 Modified release formulations containing drug-ion exchange resin complexes ➤ Subscribe
5,091,190 Delivery system for administration blood-glucose lowering drug ➤ Subscribe
6,514,496 Dispersible antibody compositions and methods for their preparation and use ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents for PFIZER Drugs

Supplementary Protection Certificates for PFIZER Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
90036-0 Sweden ➤ Subscribe PRODUCT NAME: KOMBINATION AV INSULIN DEGLUDEK OCH INSULIN ASPART; REG. NO/DATE: EU/1/12/806/001 20130121
0596 Netherlands ➤ Subscribe PRODUCT NAME: INSULINE DEGLUDEC; NATIONAL REGISTRATION NO/DATE: EU/1/12/807/004 20130123; FIRST REGISTRATION: EU EU/1/12/807/001 20130123
C0009 France ➤ Subscribe PRODUCT NAME: INSULINE GLULISINE; REGISTRATION NO/DATE IN FRANCE: EU/1/04/258/001 DU 20040927; REGISTRATION NO/DATE AT EEC: EU/1/04/285/001 DU 20040927
C/GB10/012 United Kingdom ➤ Subscribe PRODUCT NAME: A COMBINATION OF ACYCLOVIR AND HYDROCORTISONE; REGISTERED: UK PL18191/0001-0001 20091112
0625 Netherlands ➤ Subscribe PRODUCT NAME: COMBINATIE BEVATTENDE ALISKIREN, OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN, EN AMLODIPINE, OF EEN FARMACEUATISCH AANVAARDBAAR ZOUT DAARVAN; REGISTRATION NO/DATE: EU/1/11/686/001-056 20110414
0170012 00212 Estonia ➤ Subscribe PRODUCT NAME: PALBOTSIKLIIB;REG NO/DATE: EU/1/16/1147 11.11.2016
2017000040 Germany ➤ Subscribe PRODUCT NAME: SCHNELL-WIRKENDES INSULIN ASPART; REGISTRATION NO/DATE: EU/1/16/1160 20170109
00021 Netherlands ➤ Subscribe PRODUCT NAME: INSULINE ASPART EN GEKRISTALLISEERD PROTAMINE-INSULINE ASPART; NAT. REGISTRATION NO/DATE: EU/1/00/142/001 20000801; FIRST REGISTRATION: 55414015541502 2000230623
2209800/01 Switzerland ➤ Subscribe PRODUCT NAME: INSULIN DEGLUDEC + LIRAGLUTIDE; REGISTRATION NO/DATE: SWISSMEDIC 65041 12.09.2014
00C/005 Belgium ➤ Subscribe PRODUCT NAME: DOFETILIDE; REGISTRATION NO/DATE: EU/1/99/121/001 19991129
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Federal Trade Commission
Chinese Patent Office
McKesson
Fish and Richardson
Novartis
Cantor Fitzgerald
Mallinckrodt
Merck
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot